Description

In this episode, the discussants examines the following questions, raised after a Journal of Hepatology’s nomenclature article:

• Is the introduction of metabolic risk factors (MRF) for the definition of MASLD justified?
• What are the main issues regarding the measurement and thresholds for MRFs?
• Is the introduction of the MetALD category clinically justified?
• Is it necessary to worry about MRFs in a patient drinking increased or excessive amounts of alcohol and if yes, how should these be accounted for in disease classification systems?

Faculty

• Vlad Ratziu (Moderator)
• Giulio Marchesini (Faculty)
• Nancy Reau (Faculty)
• Roberto Vettor (Faculty)

Related article

• A multi-society Delphi consensus statement on new fatty liver disease nomenclature

Related episodes

• EASL Studio from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclature

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

This #EASLStudio JHEP Live discusses the newly released EASL Clinical Practice Guidelines on Acute-on-chronic liver failure (ACLF).

In particular:

• ICU admission criteria for patients with ACLF
• Treatment of infection and antibiotic selection
• Liver support
• Liver transplantation for ACLF: Sarcopenia and frailty

Faculty

• Richard Moreau (Moderator)
• Rajiv Jalan (Faculty)
• Constantine Karvellas (Faculty)
• Rakhi Maiwall (Faculty)

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

Non-alcoholic steatohepatitis (NASH) is rapidly emerging as a leading cause of chronic liver disease, presenting significant challenge due to the limited treatment options available.

This EASL Studio JHEP Live aims to explore novel and promising treatments currently being evaluated for the treatment of NASH. In particular:

• ARO-HSD, an HSD17β13 inhibitor.
• PXL065 under evaluation in the DESTINY-1 trial.
• The investigation of an FXR agonist in fibrotic NASH as part of the LIVIFY trial.

Faculty

• Prof. Vlad Ratziu (Moderator)
• Prof. Stephen Harrison (Faculty)
• Dr Rohit Loomba (Faculty)
• Dr Loey Lung-Yi Mak (Faculty)

Related articles

• A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis
• Evaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)
• Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

In honour of International NASH Day, the final episode of EASL Studio season 4 is shedding light on non-alcoholic steatohepatitis (NASH), a disease with increasing global prevalence but low awareness.

Faculty

• Zobair Younossi (Moderator)
• Alina M. Allen (Faculty)
• Sven Francque (Faculty)
• Vincent Wong (Faculty)
• Shira Zelber-Sagi (Faculty)

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

This EASL Studio episode covers the highlights of the SLD Summit 2023, including:

• Physiopathological mechanism
• Problems encountered in the cirrhotic stage in SLD
• Novelties about liver biopsies

Faculty

• Sven Francque (Moderator)
• Quentin Anstee (Faculty)
• Frank Tacke (Faculty)
• Maja Thiele (Faculty)

Related episodes

• EASL Studio S5E2: Are 30% of the global population sick? A critical view on Steatotic Liver Disease and care pathways
• EASL Studio Live from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclature
• EASL Studio S4E23: The conundrum of NASH: The growing global disease burden with low disease awareness
• EASL Studio S4E22: JHEP Live: New and promising drugs for NASH on the horizon

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

This EASL Studio is supported by Boehringer Ingelheim. EASL has received no input from Boehringer Ingelheim with regards to the content of this programme.

Description

Clinical evidence indicates that cigarette smoking negatively impacts the incidence and severity of fatty liver disease, fibrosis progression, hepatocellular carcinoma development, and the outcomes of patients with advanced liver disease. The underlying mechanisms are complex and involve different pathophysiological pathways including oxidative stress and oncogenic signals.

To coincide with World No Tobacco Day, 31 May, this EASL Studio discusses some of the pathophysiological mechanisms that drive the progression of liver disease and cancer risk in those who smoke.

Faculty

• Prof. William Alazawi (Moderator)
• Prof. Debbie Shawcross (Moderator)
• Prof. Ramon Bataller (Faculty)
• Prof. Vanessa Stadlbauer-Köllner (Faculty)

ℹ️ Please click here to access the podcast version of this EASL Studio episode.